![G. Kahn](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
G. Kahn
Direktor/Vorstandsmitglied bei
SOLID BIOSCIENCES INC.
Vermögen: 21 726 $ am 31.05.2026
Profil
G.
Clare Kahn is currently President at Clare Kahn Pharma Consulting LLC since 2016.
Independent Director at Solid Biosciences, Inc. since 2021.
Independent Director at Stoke Therapeutics, Inc. starting in 2026.
Formerly Vice President-Global Innovative Pharma at Pfizer Inc. from 2014 to 2016.
Vice President-Regulatory Affairs at GSK Plc from 1999 to 2010.
Chief Regulatory & Preclinical Development Officer at X-Vax Technology, Inc. from 2018 to 2019.
Assistant Professor at the University of Pennsylvania from 1981 to 1985.
Earned a doctorate from Royal Postgraduate Medical School in 1981.
Bekannte Unternehmensbeteiligungen
| Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
|---|---|---|---|---|
| 10.06.2026 | 2’960 ( 0% ) | 21 726 $ | 31.05.2026 |
Aktive Positionen von G. Kahn
| Unternehmen | Position | Beginn |
|---|---|---|
| SOLID BIOSCIENCES INC. | Direktor/Vorstandsmitglied | 02.03.2021 |
| STOKE THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 03.04.2026 |
Clare Kahn Pharma Consulting LLC | Präsident | 01.06.2016 |
Ehemalige bekannte Positionen von G. Kahn
| Unternehmen | Position | Ende |
|---|---|---|
| PFIZER INC. | Corporate Officer/Principal | 01.06.2016 |
| GSK PLC | General Counsel | 01.01.2010 |
University of Pennsylvania
 University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Corporate Officer/Principal | 01.01.1985 |
X-Vax Technology, Inc.
 X-Vax Technology, Inc. BiotechnologyHealth Technology Develops biotechnology products | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von G. Kahn
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
90
Beziehungen ersten Grades
8
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 8 |
|---|---|
Pfizer Inc.
 Pfizer Inc. Pharmaceuticals: MajorHealth Technology Engages in discovery, development, manufacturing, marketing, sale and distribution of biopharmaceutical products & ingredients | Health Technology |
GSK Plc
 GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Pennsylvania
University of Pennsylvania Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Solid Biosciences, Inc.
 Solid Biosciences, Inc. BiotechnologyHealth Technology Operates as a pharmaceutical company that develops treatments through gene therapy for patients with duchenne disease | Health Technology |
X-Vax Technology, Inc.
X-Vax Technology, Inc. BiotechnologyHealth Technology Develops biotechnology products | Health Technology |
Stoke Therapeutics, Inc.
 Stoke Therapeutics, Inc. BiotechnologyHealth Technology Operates as biotechnology company focused on the development of first-in-class therapeutics that selectively increase gene expression to treat genetic diseases | Health Technology |
Royal Postgraduate Medical School
 Royal Postgraduate Medical School Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Clare Kahn Pharma Consulting LLC |
